What Is the End Stage of Squamous Cell Carcinoma?

End-stage squamous cell carcinoma is defined by tumor that has grown beyond the reach of curative treatment, either because it has invaded so deeply into local tissue that surgery cannot clear it, or because it has spread to distant organs. The experience of this stage depends heavily on where the cancer started, with head and neck tumors producing especially visible and distressing complications, but some features are shared across nearly all sites: escalating pain, progressive inability to eat, metabolic disruption, and eventual organ failure. Understanding what this stage actually looks like, symptom by symptom, helps patients and families prepare for decisions that are easier to make before a crisis arrives.

What Stage IV Actually Means

Squamous cell carcinoma can arise in many places: the skin, the lining of the mouth and throat, the esophagus, the lungs, and the cervix, among others. Regardless of origin, the cancer is classified as stage IV when it meets specific criteria for advanced spread. For cutaneous (skin) SCC, stage IV means the tumor has either become unresectable in the local area or has metastasized to distant sites like the lungs, liver, or bone.¹ For head and neck SCC, the staging incorporates tumor size, lymph node involvement, and the presence of distant metastases. In all cases, the designation signals that the disease is advanced enough to sharply limit both treatment options and life expectancy.

The word “end stage” is used loosely in conversation and can mean different things to different people. Some use it to refer to any stage IV cancer. Others reserve it for the last weeks or months of life, when treatment has shifted entirely to symptom control. This article covers both the broader features of advanced, incurable SCC and the specific complications that emerge as the disease nears its conclusion.

Local Tissue Destruction and Fungating Wounds

One of the most physically and emotionally difficult features of advanced SCC is what happens when the tumor outgrows its blood supply or simply pushes through the skin. The result is a fungating wound: an open, often foul-smelling lesion that can bleed, ooze, and resist healing. These wounds develop when a primary skin cancer grows unchecked, when an underlying tumor invades upward through the skin, or when a metastatic deposit breaks the surface. SCC is one of the cancers most associated with this complication, alongside melanoma and breast cancer.

Fungating wounds are not just a cosmetic problem. They cause pain, make dressing changes difficult and sometimes agonizing, and produce odor that patients describe as profoundly isolating. In a hospice study of end-stage head and neck cancer patients, nurses reported feeling extremely distressed by the visible, odorous, and fungating tumors they were managing.² When the tumor is on the face or neck, social withdrawal often follows. Wound care at this stage focuses on controlling odor, managing drainage, preventing infection, and keeping the patient as comfortable as possible rather than attempting to heal the wound.

Pain and Nerve Invasion

Advanced SCC has a particular tendency to invade nerves, a process called perineural invasion. When tumor cells spread along a nerve sheath, they can cause burning or shooting pain, numbness, tingling, or loss of muscle function in the area that nerve supplies. This is especially common in head and neck SCC and in cutaneous SCC of the face, where major sensory nerves are close to the skin surface.³ Perineural invasion is considered a sign of aggressive disease and is associated with higher recurrence rates and worse outcomes overall.

Pain at the end stage of SCC is rarely from a single cause. It can come from the tumor pressing on surrounding structures, from bone destruction if the cancer has metastasized to the skeleton, from the fungating wounds described above, and from treatment side effects like radiation-induced tissue damage. Pain management usually requires a combination of approaches: opioid medications for baseline pain, additional drugs for nerve-related pain, and sometimes targeted radiation to painful metastatic sites. The goal shifts entirely from cure to comfort.

Airway Obstruction in Head and Neck SCC

For squamous cell carcinoma of the pharynx, larynx, or surrounding structures, one of the most feared complications of advanced disease is airway obstruction. As the tumor grows, it can physically narrow or block the passage through which a person breathes. This narrowing can happen gradually, giving some warning, or it can worsen suddenly due to bleeding into the tumor, treatment-related swelling, or a shift in the tumor’s position.⁴

When airway compromise develops, it creates an urgent clinical decision. A tracheostomy, a surgical opening in the windpipe below the tumor, can bypass the obstruction and allow the person to breathe. But for patients who are already in the final weeks of life with widely metastatic disease, that procedure carries its own risks and may not align with a person’s goals. In some cases, plans for tracheostomy have to be abandoned because the patient’s overall condition deteriorates too rapidly. The interplay between tumor burden, vascular complications, and treatment-related edema makes airway management in advanced pharyngeal SCC genuinely unpredictable.

Vascular Emergencies

Advanced head and neck SCC can erode into major blood vessels, most dangerously the carotid artery. When tumor or radiation-damaged tissue weakens the artery wall to the point of rupture, the result is carotid blowout syndrome, a rare but potentially fatal hemorrhage.⁵ This complication occurs most often in patients who have previously received radiation therapy, which weakens the vessel wall, and who still have active tumor near the artery.

In a study of 45 patients who experienced carotid blowout, roughly three-quarters had stage IV disease, and about the same proportion had active tumor at the time of the bleed. Nearly all had received prior radiation, with a mean total dose of about 63 Gy. The syndrome ranges from a “threatened” bleed, where imaging shows the vessel wall is thinning but has not yet ruptured, to an acute hemorrhage that can be massive and immediately life-threatening.⁶ Sometimes a smaller “herald bleed” precedes the major event by hours or days, offering a narrow window to prepare. Palliative care teams who work with advanced head and neck cancer patients plan explicitly for this possibility, keeping sedative medications and dark-colored towels at the bedside so that if a catastrophic bleed occurs, the focus can shift immediately to comfort and reducing the patient’s awareness of what is happening.

Hypercalcemia and Metabolic Crises

SCC, especially of the head and neck, has a well-documented tendency to cause dangerously high blood calcium levels through a paraneoplastic mechanism. The tumor produces a protein called parathyroid hormone-related protein (PTHrP), which mimics the action of the normal hormone that regulates calcium. The result is hypercalcemia: calcium levels climb, causing confusion, nausea, constipation, profound thirst, muscle weakness, and eventually cardiac arrhythmias and coma if untreated.

Research has found that hypercalcemia appeared in the majority of patients with terminal-stage head and neck SCC, and elevated PTHrP levels were confirmed in nearly all of those who developed it.⁷ A separate study found a direct relationship between PTHrP levels and calcium, suggesting that tracking the protein in the blood can help predict when hypercalcemia is coming.⁸ Hypercalcemia can be treated with intravenous fluids and medications that lower calcium, but in end-stage disease it tends to recur and eventually becomes refractory to treatment. For some patients, the drowsiness and confusion that accompany rising calcium levels may actually represent a relatively gentle path toward death compared to other complications of advanced SCC.

Wasting, Weight Loss, and Swallowing Difficulty

Cachexia, the syndrome of severe weight loss, muscle wasting, and fatigue driven by the cancer itself, is a common feature of advanced SCC. It is not simple starvation. The tumor releases inflammatory signals that rewire the body’s metabolism, increasing energy expenditure while simultaneously breaking down muscle and fat stores. A scoping review of cachexia in head and neck SCC found that the condition is driven by multiple overlapping mechanisms: reduced nutritional intake due to pain or obstruction, tumor-induced metabolic changes, and progressive loss of both fat and skeletal tissue.⁹

Swallowing difficulty, or dysphagia, compounds the problem. A tumor in the throat, esophagus, or surrounding structures can physically prevent food from passing. Even when the primary cancer is not in the digestive tract, radiation and surgery to the head and neck frequently damage the swallowing mechanism. For patients with esophageal SCC, placing a self-expanding metal stent can open the passage enough to allow eating and improve quality of life, though it does not extend survival.¹⁰ Feeding tubes are another option, but their use in the final weeks of life raises ethical questions about whether they provide genuine benefit or simply extend the dying process.

Palliative Radiation and Other Treatments

Even when cure is no longer possible, radiation therapy can still play a role. Palliative radiation is given in shorter courses at lower doses than curative treatment, with the goal of shrinking the tumor enough to relieve symptoms like pain, bleeding, or obstruction. A study of 73 patients with head and neck SCC who were not candidates for curative therapy found that palliative radiation, given as a standard short course, produced a median overall survival of about seven and a half months. The most important factor predicting who lived longer was not the specific tumor characteristics but the patient’s overall functional status at the time of treatment.¹¹

Immunotherapy with checkpoint inhibitors has changed the landscape for some patients with advanced SCC, particularly those whose tumors express certain biomarkers. These drugs work by releasing the brakes on the immune system, allowing it to attack the cancer. When they work, responses can be durable. But a subset of patients experience the opposite: rapid disease acceleration after starting immunotherapy. And for patients who are already severely debilitated, the side effects of immunotherapy may outweigh any benefit. Chemotherapy remains an option for symptom control in some cases, though its role diminishes as the patient’s functional status declines. The honest reality is that once SCC has reached its terminal phase, no systemic therapy reliably reverses the trajectory.

The Psychosocial Toll

End-stage SCC of the head and neck carries a psychosocial burden that is distinct from many other cancers, because the disease and its treatment alter the face and the ability to speak, eat, and interact socially. Research into body image distress among head and neck cancer patients has captured this vividly. Patients describe food and fluids leaking from the nose during meals, a need to always have a handkerchief ready, and a feeling that their speech sounds slurred in ways that invite judgment from others.¹² When a patient also has a visible, fungating wound on the face or neck, isolation from friends and family tends to accelerate. Depression and anxiety rates are high in this population, and they often go undertreated because clinicians are focused on the physical crisis.

For caregivers, the experience of managing end-stage head and neck SCC can be overwhelming. The combination of wound care, feeding assistance, constant monitoring for bleeding, and the emotional weight of watching a loved one’s face change is something most families are unprepared for. Hospice teams experienced in head and neck cancer can make a substantial difference, both by managing symptoms and by providing psychological support to the family.

Immunosuppressed Patients Face a Faster Course

SCC behaves more aggressively in people whose immune systems are suppressed, particularly organ transplant recipients who take medications to prevent rejection. These patients develop skin SCC at dramatically higher rates than the general population, and their cancers tend to recur more frequently, metastasize earlier, and carry higher mortality.¹³ The end-stage features described throughout this article, including fungating wounds, nerve invasion, and distant metastases, arrive sooner and sometimes with less warning in this group. For transplant recipients who develop an aggressive SCC, the clinical team faces a difficult balancing act: reducing immunosuppression may help the immune system fight the cancer but puts the transplanted organ at risk.

The Final Days

As death approaches, a recognizable pattern of decline emerges that is shared across most cancers, including SCC. In the last week of life, studies of cancer patients have found that the most common symptoms include loss of appetite in about four out of five patients, dry mouth, confusion, constipation, difficulty breathing, and difficulty swallowing.¹⁴ In the final 48 hours, the pattern shifts: noisy, moist breathing becomes the most frequent symptom, present in more than half of patients, followed by pain, restlessness, urinary incontinence, and difficulty swallowing.

For patients with head and neck SCC specifically, the final days in hospice have been described as a more or less rapid deterioration, with the median survival after hospice admission around 19 days in one study. The final phase typically follows a progression from restlessness to increasing drowsiness and eventually to irreversible coma.² Pain and secretions are managed with continuous medication, and the focus shifts entirely to keeping the patient comfortable and the family supported.

Planning for Catastrophic Events

One aspect of end-stage head and neck SCC that sets it apart from many other cancers is the possibility of sudden, dramatic complications: a massive hemorrhage from an eroded vessel, an abrupt airway obstruction, or a seizure from brain metastases. These events are terrifying for everyone present, and palliative care experts strongly recommend planning for them in advance rather than reacting in the moment.

The standard approach for patients identified as at risk, particularly those with tumors near major blood vessels or who have had a prior small bleed, involves several practical steps. The care team prepares rapid-acting sedative and pain medications in pre-drawn syringes kept at the bedside. Dark-colored towels and blankets are staged nearby, because a pool of visible bright-red blood intensifies the trauma for the patient and family. The plan of action is discussed openly with the patient (if they are able) and with caregivers: what to expect, who to call, and whether resuscitation will be attempted. When a terminal hemorrhage is anticipated within a day or two, hospice programs may activate continuous bedside nursing so the patient is never alone when it happens.

These conversations are difficult, but they are among the most valuable things a palliative care team can offer. Families who have been prepared for the possibility of a catastrophic bleed consistently report less traumatic grief afterward than those who were not warned. Advance care planning documents that specifically address these scenarios, rather than using generic language about “heroic measures,” give the medical team clearer guidance and spare the family from making decisions during a crisis they have never imagined.

Treatment Resistance and Why Tumors Stop Responding

A frustrating feature of end-stage SCC is the near-inevitability of treatment resistance. A tumor that initially responded well to chemotherapy, radiation, or immunotherapy may stop responding entirely, sometimes after months of apparent control. Research into why this happens has identified a process of genetic evolution within the tumor itself: as treatment kills off sensitive cancer cells, resistant subpopulations survive and expand. Studies of esophageal SCC treated with combination therapy have tracked new mutations emerging during treatment that were not present before it began, effectively creating a new, drug-resistant version of the cancer.¹⁵

For families, this biological reality explains why a treatment that seemed to be working can suddenly fail. It is not that the doctors chose the wrong drug or that the patient did something wrong. The tumor adapted. Recognizing this can help frame the shift from active treatment to comfort-focused care as a rational response to what the cancer has become, rather than as giving up. Hospice enrollment does not mean abandoning medicine; it means redirecting medical effort toward the problems that medicine can still solve, like pain, nausea, anxiety, and breathing difficulty, at a stage when the tumor itself is no longer a problem medicine can fix.